---
title: "AquaBounty Undertakes Debt Exchange and Preferred Stock Financing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282041859.md"
description: "AquaBounty Technologies, Inc. has exchanged $4 million in senior notes for 236,367 shares of Series A Convertible Preferred Stock and sold an additional 27,386 shares for $500,000. This move aims to reduce debt and raise equity financing. The latest analyst rating for AQB stock is a Sell with a price target of $0.82, reflecting weak financial performance and bearish technical indicators. AquaBounty focuses on genetically engineered fish and related technologies in the biotechnology sector."
datetime: "2026-04-08T12:39:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282041859.md)
  - [en](https://longbridge.com/en/news/282041859.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282041859.md)
---

# AquaBounty Undertakes Debt Exchange and Preferred Stock Financing

### Easter Sale - 70% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

AquaBounty Technologies ( (AQB) ) has shared an update.

On April 7, 2026, AquaBounty Technologies, Inc. exchanged $4 million of principal and $315,616.44 of accrued interest on its senior notes for 236,367 shares of Series A Convertible Preferred Stock, which can convert into up to 4,727,371 common shares, in a private placement. On the same date, the company also sold 27,386 additional Series A Preferred shares for $500,000 in cash, entered a placement agency agreement with Univest Securities, LLC for a 7% fee on the preferred stock sale, and designated the new preferred class via a Delaware filing, indicating a combined effort to reduce debt and raise equity financing through exempt, accredited-investor transactions.

The most recent analyst rating on (AQB) stock is a Sell with a $0.82 price target. To see the full list of analyst forecasts on AquaBounty Technologies stock, see the AQB Stock Forecast page.

**Spark’s Take on AQB Stock**

According to Spark, TipRanks’ AI Analyst, AQB is a Underperform.

The score is driven primarily by very weak financial performance (collapsed revenue, persistent losses, heavy cash burn, and negative equity), which outweighs other factors. Technical indicators also reflect a bearish trend with weak momentum. Valuation metrics do not provide meaningful support given the non-informative P/E and missing dividend yield.

To see Spark’s full report on AQB stock, click here.

**More about AquaBounty Technologies**

AquaBounty Technologies, Inc. operates in the biotechnology and aquaculture sector, focusing on genetically engineered fish and related technologies for food production. The company raises capital and manages its balance sheet through securities offerings and structured financings in the U.S. capital markets.

**Average Trading Volume:** 32,617

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $4.59M

For a thorough assessment of AQB stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [AQB.US](https://longbridge.com/en/quote/AQB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 2,970 Shares of Stock](https://longbridge.com/en/news/286489870.md)
- [ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership](https://longbridge.com/en/news/286787574.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md)